

## Transforming metastatic cancer from a terminal prognosis to a manageable disease like diabetes

PITCH VIDEO INVESTOR PANEL



lifebridge10000.com Longwood FL 

Technology Science Healthcare Social Impact Tech

OVERVIEW UPDATES WHAT PEOPLE SAY  ASK A QUESTION 

### Highlights

- 1 Our device can extend the proven benefits of Tumor Treating Fields (TTF) therapy to patients with metastatic cancer
- 2 On any given day 500,000+ cancer patients could be helped by our therapy. Without it they will die
- 3 Value creation! Tumor Treating Fields has experienced explosive growth up 736% since 2018 (Forbes)
- 4 We solve the limitations of the current therapy. 2 U.S. Patents 3rd pending. Pending in 36 counties

### Our Team



**Peter F. Travers** CEO and Founder, Managing Member of LifeBridge

He has a BA in communication from UCF. His first company was a medical ed firm that sold materials he created. He designed a marketing program that sold the training products to 3,000 hospitals.



**Lee Zehngobot M.D.** Medical Advisor

Dr. Lee Zehngobot has served as the Director of Clinical Research, Florida Hospital Cancer Institute in Orlando since 2007 and has participated as Principal Investigator and Co-Investigator on numerous clinical studies. Medical advisor to the company



**Ken Watkins** Founding Member and Chief Technologist

Mr. Watkins has 40 years of experience in the electronic engineering field, including 17 with Northrop Grumman Corp. While at Northrup he was responsible for 30 electrical engineers.

SEE MORE

### Pitch

Company Purpose



LifeBridge can transform metastatic cancer from a terminal condition into a manageable chronic disease like diabetes via our patented ATTF system

LIFEBRIDGE 10000

"Because they have more life to live..."

## GLOBAL METASTATIC CANCER


## Problem



- 90% of all cancer deaths are from metastatic disease.
- All forms of therapies fail these patients including chemo, radiation and surgery.
- Deaths are often excruciating.
- Patients and their doctors are desperately seeking high quality extended life

LIFEBRIDGE 10000

## Solution



### Adaptive Tumor Treating Fields (ATTF) by LifeBridge 10000

- No side effects- patients work, free to live life
- Core therapy successfully tested on 18 tumor types (can treat millions of patients)
- Patent protected improvements revolutionizes present TTF therapy
- We offer the only TTF therapy designed for the metastatic patient
- Uniquely addresses cancer patients who continue to remain underserved, yet account for 90% of all cancer deaths

## Why Now?


LIFEBRIDGE 10000



LIFEBRIDGE 10000

## Market Size

### TOTAL ADDRESSABLE MARKET (TAM): GLOBAL METASTATIC CANCER



## Competition for LifeBridge's ATTF Therapy

LIFEBRIDGE 10000

## COMPETITIVE THERAPIES USED TO TREAT METASTATIC DISEASE

- **Radiation:** The more advanced the disease the more radiation is used to minimize suffering not for prolonging life  
– (Nausea, vomiting, extreme tiredness, etc.)
- **Chemo Therapies:** can be used on metastatic disease until the end, but all eventually fail (overall poor quality of life, nausea, vomiting, fatigue, can cause nerve damage, hair loss, may cause cognitive dysfunction, etc.)
- **Surgery:** Not a primary therapy for metastatic disease
- **Immune Therapy:** Experimental (fatigue, diarrhea, fever, nausea, inflammation of the lungs, etc.)
- **All of the Above:** Quality of life endured is so poor metastatic patients ask themselves "Is it worth it"
- **Novocure Fixed Tumor Treating Fields:** Unable to treat metastatic disease in two or more locations (which is most metastatic cancer patients...)
- However TTF has no significant side effects other than minor skin irritation...

ALL THESE FAIL THE METASTATIC PATIENT... SO MILLIONS OF PATIENTS DIE...  
→ LIFEBRIDGE IS BUILT FROM THE GROUND UP TO TREAT THEM!

LIFEBRIDGE 10000


## Competition Continued

Only 2 companies control TTF patents: Novocure & LifeBridge 10000

Novocure's 16 blocking patents are aging/expiring rapidly					
Anticipated Expiration Year	2021	2022	2023	2024	Total expired by 06/18/2024
Number of Novocure Patents Expiring	2	5	3	6	16

Once these patents expire, LifeBridge will have freedom to operate in US  
All LifeBridge Controlled Patents Have 17 to 20 Years Remaining!

## Product




## REVENUE PLAN (\$M) medical tourism



## GROSS MARGIN

- Each LifeBridge ATTF system (LB10000) has a commercial life of 12 patient-months.
- Average Net Gross Margin = 80% at early production levels.
- This is in line with industry comps.

**Gross margin will increase with growth in production rates, regular product cost reductions and wider third-party reimbursement coverage**



Team Continued

LIFEBRIDGE 10000 ADVISORY BOARD AND ADVISORS



Dianna Latour  
Operating Partner  
for LFE Capital



Scott Hubbard  
Business  
Development  
Manager at Strategis  
Consulting, LLC



Avi Roop  
Chairman of the  
Board and CEO of  
Miret Surgical Inc




Mike Winegar  
Winegar Consulting  
Regulatory Affairs Strategy

### Our team has put over 60 Devices through the FDA Approval Process

LIFEBRIDGE 10000

12



We are only raising up to \$250k in this Wefunder offering. See accompanying Form C for our use of proceeds.

### The Opportunity

- Tumor Treating Fields are prescribed and reimbursed globally
- Effective against 18+ types of cancer (clinical and pre-clinical studies)
- Novocure currently the only TTF provider (over \$463M revenue from single cancer)
  - Key patents expiring by 2025
  - Metastatic disease not addressed in their 10 year pipeline
- Metastatic disease kills 90% of cancer patients, not primary tumors
  - Yet only 5% - 7% of R&D spend on Metastatic treatments
- LifeBridge's patented system designed from the ground up to treat metastatic disease
- Successful \$1.2M seed round closed, \$4.0M A round opened
- This will fund animal safety study, human pilot & all operations for 24 months

LifeBridge uniquely positioned to address \$23B underserved metastatic patient population with its patented Adaptive Tumor Treating Field (ATTF) system!